Complain about a product or service

Vioxx Study Authors Backtrack On Claim

June 26, 2006

Related Stories • Pfizer Pays Record $2.3 Billion Settlement Over Illegal Marketing Charges • Court Snuffs Vioxx Suit • Pfizer Pays $894 Million to Settle NSAID Claims • Researchers Claim Vioxx Safety Study Was Actually Marketing Plan • First Vioxx Judgment Overturned On Appeal • Merck Agrees to Pay $58 Million to Settle Vioxx Claims • Researchers Claim Merck Cooked Vioxx Data • Common Pain Relievers May Boost Muscle Mass • More Painkillers Can Cause More Pain • Merck Caves, Agrees To $4.85 Billion Vioxx Settlement • New York Sues Vioxx Maker over Drug’s Risks • Merck Wins Vioxx Case In Illinois • Judge Rules Out Vioxx "Super" Class Action • FDA Critic Blasts Merck's Vioxx Replacement • Merck Loses New Orleans Vioxx Case • Merck Wins Latest Vioxx Suit • Vioxx Study Authors Backtrack On Claim • Older Painkillers May Increase Heart Attack Risk • More about Vioxx --- Other NSAIDs • Bextra • Celebrex • Dangers of Other Vioxx-Type Drugs • Vioxx Alternatives • Aleve Ingredient Seen as Health Risk

Merck & Co., facing over 1,000 lawsuits because of its now withdrawn painkiller Vioxx, has based much of its defense on research suggesting it takes months of Vioxx use to cause cardiovascular problems. But now the journal that originally advanced that position is backing away.

In a correction on its Web site, the New England Journal of Medicine disavowed the conclusion that it takes 18 months for Vioxx risks to appear. The correction alters the wording of the research paper and the abstract. The research originally appeared in early 2005.

Merck pulled Vioxx, a popular pain reliever widely used by arthritis patients, off the market in September 2004, saying it was "putting patient safety first." However, the Wall Street Journal reported earlier that company officials had fought for years to protect the highly profitable drug and to keep news of the health risks quiet.

Vioxx was a big moneymaker for Merck, generating about $2.5 billion in yearly sales.

So far, Merck has won two Vioxx liability cases and lost two. However, hundreds more are awaiting trial.

The latest trial, in which Merck plaintiffs were awarded a total of $13.5 million, was considered significant because it was the first to involve patients taking the drug for a long period of time.

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Share		Follow us on Twitter.